We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
With the pharmaceutical industry closely tracking pricing developments, Johnson & Johnson executives shared the drug giant's perspective after reporting second-quarter results Tuesday.